Clinilabs, a US-based contract research organisation (CRO) focused on early-phase and specialty clinical drug development services, has formed a strategic alliance with H&J CRO International, a full-service CRO with headquarters in New Jersey and two branch offices in China.
Under the agreement, the two companies will provide clinical drug development services to pharmaceutical and biotechnology companies worldwide through an exchange of knowledge and resources.
The companies will combine their business development, project management and data management operations internationally. The aim is that Clinilabs will leverage the relationship to expand its coverage throughout Asia, while H&J will use Clinilabs as a gateway to business growth in North America.
H&J’s two branch offices are in Beijing and Shanghai. The parent company, H&J (Beijing) Medinfor Consultants Ltd, was established in 2003. H&J CRO International bills itself as a global CRO specialising in regulatory affairs, clinical trials, clinical data management, SAS (Statistical Analysis System) programming, biostatistics and medical writing.
Dr Gary Zammit, president and chief executive officer of Clinilabs, said the alliance enabled the company to manage early-phase and speciality trials in the US while offering clients the cost efficiencies available in the Asian markets.
